We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması.
- Authors
Altınkaynak, Mustafa; Göksoy, Yağmur; Şenkal, Naci; Tor, Yavuz Burak; Akpınar, Timur; Köse, Murat
- Abstract
Introduction This study investigated the efficacy and safety of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, in the treatment of obesity. Materials and Methods The study enrolled 303 patients over 18 years of age with overweight or obesity (201 female, mean age 40.9 years). The records of patients admitted from the Internal Medicine Outpatient Clinic between 2018 and 2021 were retrospectively reviewed. Patients taking liraglutide (3 mg) daily in combination with diet and physical activity were included. Body mass index (BMI), drug efficacy, and side effects were evaluated once monthly. Results Participants' BMI was evaluated; 80 of them were overweight, 128 of them were obese stage 1, 61 of them were obese stage 2, and 34 of them were obese stage 3. Patients were divided into 3 groups according to the duration of liraglutide intake (1-4 months for 233 patients, 5-8 months for 59 patients, and = 9 months for 11 patients). Mean age was 41.2±10.5, 39.8±10.9, and 40.2±10.4; mean BMI was 34.3±2.4 kg/m2, 33.9±4.2 kg/m2, and 39.5±5.1 kg/m2; and mean weight loss was 6.4 kg, 12.5 kg, and 21 kg, respectively. All groups experienced significant weight loss compared with their baseline weight (p<0.001). The percentage of patients achieving weight loss goal was 46% at month 1, 86% at 2 months, and 90% at 3 months. In addition, the most common side effect was nausea. Conclusion In combination with lifestyle modification, liraglutide was well tolerated and resulted in significant weight loss, especially using for more than 6 months.
- Publication
Sakarya Tıp Dergisi, 2023, Vol 13, Issue 3, p334
- ISSN
2146-2585
- Publication type
Article
- DOI
10.31832/smj.1320355